Key information

🔎 Fund Overview

Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).